Reportstack’s latest report on PharmaPoint: Schizophrenia – Global Drug Forecast and Market Analysis to 2022 states that out of the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK and Japan), the latter will experience the greatest expansion over the forecast period. It will be followed by the UK and French markets, which are expected to achieve CAGRs of 5.58% and 4.65%, respectively. A key driver behind Japan’s schizophrenia market revenue growth will be the doubling of available therapy options between 2012 and 2022, which will offer patients greater autonomy.
Kyle Nicholson, PharmD, GlobalData’s Analyst covering Neurology, says: “The Japanese schizophrenia market is young in comparison to those of the US and European (EU) countries. During the forecast period, Japan will experience 11 new product launches and only five patent expirations. “Disease management in this country involves using long-acting injectable (LAI) antipsychotics less often than the US and EU regions. However, the role of these drugs in schizophrenia treatment is undergoing a growing popularity in Japan, and we expect to see a rapid uptake of new LAI therapies in the country over the coming years.”
Despite this, a number of barriers will stand in the way of further growth in Japan’s schizophrenia treatment market. These include biennial price reductions, which affect the profits of pharmaceuticals the longer they are on the market, and additional regulatory procedures involved in the drug approval process. Nicholson continues: “The Japanese drug market is the second largest in the world, but in order for a foreign-developed medication to become available, the country’s Ministry of Health, Labor and Welfare requires that the drug is re-examined before a marketing application can be approved. Foreign drug applications must also be submitted in Japanese.
“These regulations can result in delayed launches of new products and the temporary restriction of the most current medications until the requirements are met, subsequently posing a challenge to a higher level of market revenue growth by 2022,” the analyst concludes. The companies mentioned in this report are Otsuka, Lundbeck, Bristol-Myers Squibb, Merck
Forest, Vanda, Novartis, Sunovion, Eli Lilly, Johnson & Johnson, AstraZeneca, Alkermes, Pfizer, Roche and EnVivo. Key drugs in clinical development are Aripiprazole Lauroxil , Cariprazine, Brexpiprazole, Zicronapine, Bitopertin and EVP-6124 . More details and table of contents for this report can be found by visiting PharmaPoint: Schizophrenia – Global Drug Forecast and Market Analysis to 2022.